Zarnestra (R115777) : Johnson & Johnson : Farnesyl transferase inhibitor

Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients with Advanced NSCLC (PubMed)
Study published in the May 1, 2003 issue of the Journal of Clinical Oncology to define the efficacy and pharmacodynamics of R115777, a farnesyl transferase inhibitor, in the first-line treatment of patients with NSCLC. Concluded that single-agent R115777 was well tolerated in patients with advanced NSCLC, but demonstrated minimal clinical activity. Inhibition of farnesylation in vivo was consistently documented. Recommends that future studies of this agent in NSCLC should be in combination with systemic therapy. [5/03]